Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
Journal
Clinical Gastroenterology and Hepatology
Journal Volume
20
Journal Issue
5
Pages
1151-1162.e6
Date Issued
2022
Author(s)
Huang C.-F.
Tseng K.-C.
Cheng P.-N.
Hung C.-H.
Lo C.-C.
Peng C.-Y.
Bair M.-J.
Yeh M.-L.
Chen C.-H.
Lee P.-L.
Lin C.-Y.
Kuo H.-T.
Chen C.-T.
Yang C.-C.
Huang J.-F.
Tai C.-M.
Hu J.-T.
Lin C.-L.
Su W.-W.
Tsai W.-L.
Huang Y.-H.
Cheng C.-Y.
Lin C.-L.
Wang C.-C.
Yang S.-S.
Mo L.-R.
Chen G.-Y.
Chang C.-C.
Wang S.-J.
Huang C.-S.
Hsieh T.-Y.
Lin C.-W.
Lee T.-H.
Chong L.-W.
Huang C.-W.
Chang S.-N.
Tsai M.-C.
Lin H.-C.
Lee M.-H.
Tsai P.-C.
Dai C.-Y.
Chuang W.-L.
Chen C.-Y.
Yu M.-L.
Abstract
Sofosbuvir is approved for chronic hepatitis C (CHC) patients with severe chronic kidney disease (CKD). The impact of sofosbuvir-based therapy on renal function augmentation on a real-world nationwide basis is elusive. The 12,995 CHC patients treated with sofosbuvir-based (n = 6802) or non-sofosbuvir-based (n = 6193) regimens were retrieved from the Taiwan nationwide real-world HCV Registry Program. Serial estimated glomerular filtration rate (eGFR) levels were measured at baseline, end of treatment (EOT), and end of follow-up (EOF) (3 months after EOT). The eGFR decreased from baseline (91.4 mL/min/1.73 m2) to EOT (88.4 mL/min/1.73 m2; P 90 mL/min/1.73 m2 was the only factor independently associated with significant slope coefficient differences of eGFR (-1.98 mL/min/1.73 m2; 95% confidence interval, -2.24 to -1.72; P < .001). The use of sofosbuvir was not an independent factor associated with eGFR change. Both sofosbuvir and non-sofosbuvir-based regimens restored renal function in CHC patients with CKD, especially in those with significant renal function impairment.
SDGs
Publisher
W.B. Saunders
Type
journal article